{"disease":{"id":"pediatric","name":"pediatric"},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Refractory, moderate to severe atopic dermatitis in adults and pediatric patients 12 years of age and older not adequately controlled with other systemic therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in pediatric patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"chembl-chembl48361","indication_name":"Reduction of VTE recurrence in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"chembl-chembl48361","indication_name":"Treatment of VTE in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"valsartan","indication_name":"Symptomatic heart failure in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diovan","generic_name":"VALSARTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":"447","mechanism":"Diovan works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"oxbryta","indication_name":"Treatment of sickle cell disease (SCD) in pediatric patients 4 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxbryta","generic_name":"Voxelotor","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Hemoglobin S (HbS)","drug_class":"Hemoglobin S polymerization inhibitor","quality_score":10,"revenue":"250","mechanism":"Hemoglobin S polymerization inhibitor that binds HbS 1:1 and increases oxygen affinity."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"neo-bladder-construct","indication_name":"BRAF V600E Mutation-Positive Low-Grade Glioma in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1751","indication_name":"Heart Failure in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DIGOXIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cardiac Glycoside [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl941","indication_name":"Newly Diagnosed Ph+ ALL in Pediatrics","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IMATINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"fremanezumab-vfrm","indication_name":"Preventive treatment of episodic migraine in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fremanezumab-Vfrm","company_name":"Manhattan Beach Orthodontics","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide (CGRP)","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Fremanezumab-vfrm binds to CGRP and blocks its interaction with the receptor."},{"drug_id":"chembl-chembl1200641","indication_name":"Skeletal Muscle Relaxation During Pediatric Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CISATRACURIUM BESYLATE","company_name":"","drug_phase":"marketed","molecular_target":"cholinergic receptors","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Cisatracurium besylate blocks neuromuscular transmission by competitively binding to cholinergic receptors and antagonizing acetylcholine."},{"drug_id":"ethacrynic-acid","indication_name":"Congenital Heart Disease in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Edecrin","generic_name":"ETHACRYNIC ACID","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glutathione S-transferase P","drug_class":"Loop Diuretic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ethacrynic-acid","indication_name":"Nephrotic Syndrome in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Edecrin","generic_name":"ETHACRYNIC ACID","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glutathione S-transferase P","drug_class":"Loop Diuretic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"furosemide-injection","indication_name":"Edema in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Furosemide Injection","company_name":"Johannes Grand","drug_phase":"marketed","molecular_target":"","drug_class":"Loop Diuretic [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"selumetinib","indication_name":"Treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."},{"drug_id":"selumetinib","indication_name":"Treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."},{"drug_id":"calaspargase","indication_name":"Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Asparlas","generic_name":"calaspargase","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"L-asparagine","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Calaspargase is an L-asparaginase enzyme that catalyzes the conversion of L-asparagine into aspartic acid and ammonia, leading to the depletion of plasma asparagine and the death of leukemic cells."},{"drug_id":"calaspargase","indication_name":"Acute Lymphoblastic Leukemia (ALL) in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Asparlas","generic_name":"calaspargase","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"L-asparagine","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Calaspargase is an L-asparaginase enzyme that catalyzes the conversion of L-asparagine into aspartic acid and ammonia, leading to the depletion of plasma asparagine and the death of leukemic cells."},{"drug_id":"fabrazyme-agalsidase-beta","indication_name":"Treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fabrazyme (agalsidase beta)","company_name":"Genzyme, a Sanofi Company","drug_phase":"marketed","molecular_target":"α-galactosidase A (GLA gene product); substrate: globotriaosylceramide (GL-3)","drug_class":"Enzyme replacement therapy (ERT); recombinant enzyme","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"multihance-0-1-mmol-kg","indication_name":"MRI of the central nervous system (CNS) in adults and pediatric patients (including term neonates) to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MultiHance 0.1 mmol/kg","company_name":"Bracco Diagnostics, Inc","drug_phase":"marketed","molecular_target":"Water protons in tissue; blood-brain barrier; vascular endothelium","drug_class":"Paramagnetic contrast agent; gadolinium-based MRI contrast medium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fragmin","indication_name":"Treatment of symptomatic venous thromboembolism to reduce recurrence in pediatric patients from birth (gestational age at least 35 weeks)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Cultured Autologous Tissue-Engineered Skin Substitute for the Treatment of Wound Healing in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Cultured Autologous Tissue-Engineered Skin Substitute for the Treatment of Wound Healing in Wound Care in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Cultured Autologous Tissue-Engineered Skin Substitute for the Treatment of Wound Healing in Wound Care in Wound Care in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Cultured Autologous Tissue-Engineered Skin Substitute for the Treatment of Wound Healing in Wound Care in Wound Care in Wound Care in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Cultured Autologous Tissue-Engineered Skin Substitute for the Treatment of Wound Healing in Wound Care in Wound Care in Wound Care in Wound Care in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Cultured Autologous Tissue-Engineered Skin Substitute for the Treatment of Wound Healing in Wound Care in Wound Care in Wound Care in Wound Care in Wound Care in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Cultured Autologous Tissue-Engineered Skin Substitute for the Treatment of Wound Healing in Wound Care in Wound Care in Wound Care in Wound Care in Wound Care in Wound Care in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"nirmatrelvir-ritonavir","indication_name":"Treatment of mild to moderate COVID-19 in adults and pediatric patients (5 years of age and older) who weigh at least 40 kg.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"nirmatrelvir-ritonavir","generic_name":"nirmatrelvir-ritonavir","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 protease enzyme","drug_class":"Protease inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"fragmin","indication_name":"Treatment of Symptomatic VTE in Pediatric Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"levoxyl","indication_name":"Hypothyroidism in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levoxyl","generic_name":"Levothyroxine Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Thyroid receptor proteins attached to DNA","drug_class":"Thyroid hormone replacement","quality_score":10,"revenue":null,"mechanism":"Levothyroxine binds thyroid receptors in cell nuclei to activate gene transcription and protein synthesis."},{"drug_id":"rabeprazole-40-mg","indication_name":"Erosive Esophagitis in Pediatric Patients 1 to 11 Years Old","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rabeprazole 40 mg","generic_name":"rabeprazole-40-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"H+/K+ ATPase","drug_class":"Proton Pump Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rabeprazole-40-mg","indication_name":"Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years Old","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rabeprazole 40 mg","generic_name":"rabeprazole-40-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"H+/K+ ATPase","drug_class":"Proton Pump Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"part-a-atm-avi-single-dose-cohorts-1-4","indication_name":"Treatment of COVID-19 in adults and pediatric patients (12 years of age and older) who are at high risk of progression to severe COVID-19, including those who are hospitalized due to COVID-19 or who have mild to moderate COVID-19 with at least one risk factor for progression to severe COVID-19 (e.g., older age, certain chronic medical conditions)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part A: ATM-AVI Single Dose, Cohorts 1-4","generic_name":"part-a-atm-avi-single-dose-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"part-a-atm-avi-single-dose-cohorts-1-4","indication_name":"Prevention of COVID-19 in adults and pediatric patients (12 years of age and older) who are at high risk of COVID-19","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part A: ATM-AVI Single Dose, Cohorts 1-4","generic_name":"part-a-atm-avi-single-dose-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"tovorafenib","indication_name":"relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ojemda","generic_name":"TOVORAFENIB","company_name":"Day One Biopharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival."},{"drug_id":"tovorafenib","indication_name":"relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ojemda","generic_name":"TOVORAFENIB","company_name":"Day One Biopharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival."},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"ngenla-somatrogon","indication_name":"Idiopathic short stature in pediatric patients 2 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NGENLA (Somatrogon)","generic_name":"ngenla-somatrogon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant human growth hormone","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ngenla-somatrogon","indication_name":"Short stature associated with Turner syndrome in pediatric patients 2 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NGENLA (Somatrogon)","generic_name":"ngenla-somatrogon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant human growth hormone","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ngenla-somatrogon","indication_name":"Short stature associated with SHOX deficiency in pediatric patients 2 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NGENLA (Somatrogon)","generic_name":"ngenla-somatrogon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant human growth hormone","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ngenla-somatrogon","indication_name":"Short stature associated with idiopathic growth hormone deficiency in pediatric patients 2 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NGENLA (Somatrogon)","generic_name":"ngenla-somatrogon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant human growth hormone","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ngenla-somatrogon","indication_name":"Short stature associated with other causes of growth hormone deficiency in pediatric patients 2 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NGENLA (Somatrogon)","generic_name":"ngenla-somatrogon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant human growth hormone","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"cisatracurium-besylate","indication_name":"Tracheal intubation in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nimbex","generic_name":"Cisatracurium Besylate","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Acetylcholine receptor","drug_class":"Nondepolarizing Neuromuscular Blocker","quality_score":10,"revenue":null,"mechanism":"Nimbex works by blocking the action of acetylcholine at the neuromuscular junction, preventing muscle contraction."},{"drug_id":"cisatracurium-besylate","indication_name":"Skeletal muscle relaxation during surgery in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nimbex","generic_name":"Cisatracurium Besylate","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Acetylcholine receptor","drug_class":"Nondepolarizing Neuromuscular Blocker","quality_score":10,"revenue":null,"mechanism":"Nimbex works by blocking the action of acetylcholine at the neuromuscular junction, preventing muscle contraction."},{"drug_id":"dabigatran-etexilate","indication_name":"Treatment of VTE in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"dabigatran-etexilate","indication_name":"Reduction of VTE recurrence in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"lonapegsomatropin-tcgd","indication_name":"Pediatric Growth Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SKYTROFA","generic_name":"LONAPEGSOMATROPIN-TCGD","company_name":"ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S","drug_phase":"marketed","molecular_target":"growth hormone (GH) receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":"SKYTROFA binds to the GH receptor, triggering signal transduction and various pharmacodynamic effects, including growth stimulation in pediatric GHD."},{"drug_id":"daunorubicin-hydrochloride","indication_name":"Remission induction in pediatric and adult acute lymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAUNORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in pediatric patients (excluding cerebral palsy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."}],"pipeline":[{"drug_id":"rimegepant-75-mg","indication_name":"Acute treatment of migraine in pediatric subjects","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."},{"drug_id":"mesalamine","indication_name":"Pediatric ulcerative colitis","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MESALAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Cyclooxygenase","drug_class":"Aminosalicylate [EPC]","quality_score":75,"revenue":null,"mechanism":"Mesalamine reduces inflammation in the colon by blocking cyclooxygenase and inhibiting prostaglandin production."}],"offLabel":[],"totalMarketed":117,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT03948698","title":"TB Innovation Project: A Pre- and Post- Implementation Assessment (TIPPI)","phase":"","overall_status":"COMPLETED","enrollment_count":4159533,"lead_sponsor_name":"Elizabeth Glaser Pediatric AIDS Foundation","has_results":true},{"nct_id":"NCT03971344","title":"Impact of Serious Pediatric Illness on Parent and Sibling Health","phase":"","overall_status":"COMPLETED","enrollment_count":161000,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT03494998","title":"Refining and Testing the Diagnostic Accuracy of PAT-POPS","phase":"","overall_status":"UNKNOWN","enrollment_count":80000,"lead_sponsor_name":"Pennine Acute Hospitals NHS Trust","has_results":false},{"nct_id":"NCT06903897","title":"Social Needs Screening and Chronic Diseases Study (WE CARE)","phase":"NA","overall_status":"RECRUITING","enrollment_count":68000,"lead_sponsor_name":"University of Massachusetts, Worcester","has_results":false},{"nct_id":"NCT01117168","title":"Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57816,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04517760","title":"Evaluating an HIV Risk Screening Tool for Orphans and Vulnerable Children in Tanzania","phase":"","overall_status":"COMPLETED","enrollment_count":21080,"lead_sponsor_name":"Elizabeth Glaser Pediatric AIDS Foundation","has_results":false},{"nct_id":"NCT05169411","title":"Preserving Kidney Function in Children With Chronic Kidney Disease","phase":"","overall_status":"COMPLETED","enrollment_count":20240,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT05818215","title":"Impact of the Qatar 2022 FIFA World Cup on PED Use and Misuse Patterns","phase":"","overall_status":"COMPLETED","enrollment_count":18000,"lead_sponsor_name":"Pediatric Clinical Research Platform","has_results":false},{"nct_id":"NCT04574895","title":"Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events","phase":"NA","overall_status":"COMPLETED","enrollment_count":17427,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT04717349","title":"Data Collection Study of Pediatric and Adolescent Gynecology Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":11000,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT04330261","title":"Clinical Characteristics and Outcomes of Pediatric COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":10610,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT04011761","title":"Effects of Expert Arbitration on Clinical Outcomes When Disputes Over Diagnosis Arise Between Physicians and Their Artificial Intelligence Counterparts: a Randomized, Multicenter Trial in Pediatric Outpatients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT06166706","title":"Current Practice of Ventilation Strategies in Children Undergoing General Anesthesia","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT06481644","title":"Asia Pediatric Intensive Care Epidemiology and Outcomes Study","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"KK Women's and Children's Hospital","has_results":false},{"nct_id":"NCT03739827","title":"Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03063216","title":"Shanghai Pediatric Cataract Study","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Evidence Based Cataract Study Group","has_results":false},{"nct_id":"NCT03824067","title":"Impact of Point-of-Care EID for HIV-Exposed Infants","phase":"NA","overall_status":"COMPLETED","enrollment_count":9539,"lead_sponsor_name":"Elizabeth Glaser Pediatric AIDS Foundation","has_results":false},{"nct_id":"NCT03994419","title":"PErioperAtive CHildhood ObesitY","phase":"","overall_status":"UNKNOWN","enrollment_count":8000,"lead_sponsor_name":"University Hospital Southampton NHS Foundation Trust","has_results":false},{"nct_id":"NCT04902391","title":"A Patient-Partnered, Pan-Canadian, Comparative Effectiveness Evaluation of an Acute Pediatric Mental Health and Addiction Care Bundle","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6800,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT07259629","title":"Fasting Induced Hypoglycaemia in Anaesthetised Paediatric Patients","phase":"","overall_status":"RECRUITING","enrollment_count":6580,"lead_sponsor_name":"Guy's and St Thomas' NHS Foundation Trust","has_results":false},{"nct_id":"NCT05670262","title":"The Roles of Human Microbiome and Vitamin D in the Development of Childhood Allergic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"China Medical University Hospital","has_results":false},{"nct_id":"NCT04112459","title":"LongVentKids Study","phase":"","overall_status":"UNKNOWN","enrollment_count":6000,"lead_sponsor_name":"St. Justine's Hospital","has_results":false},{"nct_id":"NCT03153722","title":"Pediatric Ward Discharge Quality Improvement","phase":"NA","overall_status":"COMPLETED","enrollment_count":5478,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT03643276","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Martin Schrappe","has_results":false},{"nct_id":"NCT05472844","title":"The Cohort Study of Pediatric Cataract","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT00001186","title":"Psychological Benefits of a Normalized Camping Experience for Children With Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03334669","title":"Family-centered Obesity Prevention: Communities for Healthy Living (CHL)","phase":"NA","overall_status":"TERMINATED","enrollment_count":4999,"lead_sponsor_name":"Boston College","has_results":false},{"nct_id":"NCT03359421","title":"Trauma Routing Algorithm for Pediatrics","phase":"","overall_status":"COMPLETED","enrollment_count":4801,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT03770364","title":"Peri-operative Hypothermia in Children","phase":"","overall_status":"COMPLETED","enrollment_count":4500,"lead_sponsor_name":"KK Women's and Children's Hospital","has_results":false},{"nct_id":"NCT04351035","title":"National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry","phase":"","overall_status":"COMPLETED","enrollment_count":4303,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT07489378","title":"NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07494799","title":"Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3890,"lead_sponsor_name":"Tianjin Medical University Eye Hospital","has_results":false},{"nct_id":"NCT04206878","title":"Evaluating the Feasibility of Point of Care Birth Testing in Eswatini","phase":"","overall_status":"COMPLETED","enrollment_count":3316,"lead_sponsor_name":"Elizabeth Glaser Pediatric AIDS Foundation","has_results":false},{"nct_id":"NCT02562248","title":"Improving Anxiety Detection in Pediatrics Using Health Information Technology","phase":"NA","overall_status":"COMPLETED","enrollment_count":3267,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT07437183","title":"A Multicenter Clinical Study on the Optimization of Timing and Efficacy Evaluation of Bronchoscopic Intervention in Pediatric Severe Pneumonia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":3168,"lead_sponsor_name":"The Children's Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT06592118","title":"Clinical and Surgical Outcomes of Thyroid Carcinoma in Children and Adolescents","phase":"","overall_status":"COMPLETED","enrollment_count":3068,"lead_sponsor_name":"Dezhou Hospital Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT06621810","title":"Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"German Cancer Research Center","has_results":false},{"nct_id":"NCT06177756","title":"Targeted Approach to Prevent Early Obesity","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Azienda Ospedaliera Universitaria Integrata Verona","has_results":false},{"nct_id":"NCT05345353","title":"Childhood Obesity, Lifestyle Interventions and Weight Development","phase":"","overall_status":"COMPLETED","enrollment_count":2898,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05095012","title":"RECOVER Clinical Pathway for Pediatric Concussion","phase":"NA","overall_status":"COMPLETED","enrollment_count":2878,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT02491294","title":"Fuel for Fun: Cooking With Kids Plus Parents and Play","phase":"NA","overall_status":"COMPLETED","enrollment_count":2640,"lead_sponsor_name":"Colorado State University","has_results":false},{"nct_id":"NCT06152770","title":"Comparison of Turkish Children's Actual Weights With Which Predicted Weights by Estimation Methods","phase":"","overall_status":"UNKNOWN","enrollment_count":2600,"lead_sponsor_name":"Bozok University","has_results":false},{"nct_id":"NCT07473518","title":"Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":2550,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT04456751","title":"Is Redo Pediatric Cardiac Surgery a Risk Factor for Transfusion?","phase":"","overall_status":"COMPLETED","enrollment_count":2439,"lead_sponsor_name":"Brugmann University Hospital","has_results":false},{"nct_id":"NCT02819778","title":"Study Assessing Evaluation of the Interest of Serum S100B Protein Determination in the Management of Pediatric Mild Traumatic Brain Injury","phase":"NA","overall_status":"COMPLETED","enrollment_count":2209,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT04649242","title":"Randomized Study in Children and Adolescents With Migraine: Acute Treatment","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04406441","title":"Patient-Clinic-Community Integration to Prevent Obesity Among Rural Preschool Children","phase":"NA","overall_status":"COMPLETED","enrollment_count":2040,"lead_sponsor_name":"Geisinger Clinic","has_results":true},{"nct_id":"NCT03367832","title":"South African Paediatric Surgical Outcomes Study (SAPSOS)","phase":"","overall_status":"COMPLETED","enrollment_count":2025,"lead_sponsor_name":"University of KwaZulu","has_results":false},{"nct_id":"NCT07150676","title":"Harmonized Clinical and Biological Database for Integrated Research Into the Management of Pediatric Acute Myeloid Leukemia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}